Moloney Securities Asset Management LLC Acquires 45,296 Shares of Moderna, Inc. (NASDAQ:MRNA)

Moloney Securities Asset Management LLC lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 933.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,150 shares of the company's stock after purchasing an additional 45,296 shares during the quarter. Moloney Securities Asset Management LLC's holdings in Moderna were worth $1,422,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Itau Unibanco Holding S.A. increased its position in shares of Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after purchasing an additional 343 shares during the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Moderna by 0.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock worth $3,099,000 after acquiring an additional 345 shares during the period. Larson Financial Group LLC boosted its stake in shares of Moderna by 39.1% during the 4th quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock worth $53,000 after acquiring an additional 356 shares during the period. Deseret Mutual Benefit Administrators boosted its stake in shares of Moderna by 53.3% during the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock worth $32,000 after acquiring an additional 392 shares during the period. Finally, Parallel Advisors LLC boosted its stake in shares of Moderna by 11.4% during the 1st quarter. Parallel Advisors LLC now owns 4,403 shares of the company's stock worth $125,000 after acquiring an additional 451 shares during the period. Institutional investors and hedge funds own 75.33% of the company's stock.

Moderna Stock Performance

Shares of MRNA stock traded down $0.94 on Friday, hitting $33.34. The company had a trading volume of 4,535,502 shares, compared to its average volume of 8,830,844. The firm has a market cap of $12.89 billion, a P/E ratio of -3.82 and a beta of 1.84. The stock's 50-day moving average is $27.09 and its two-hundred day moving average is $31.26. Moderna, Inc. has a twelve month low of $23.15 and a twelve month high of $129.39.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share for the quarter, beating the consensus estimate of ($2.92) by $0.40. The company had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The business's quarterly revenue was down 35.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($3.07) earnings per share. Equities research analysts predict that Moderna, Inc. will post -9.61 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently issued reports on MRNA shares. UBS Group reduced their price target on Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Citigroup started coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target for the company. Royal Bank Of Canada reduced their price target on Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Morgan Stanley reduced their price target on Moderna from $39.00 to $32.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. Finally, Evercore ISI reduced their price target on Moderna from $50.00 to $32.00 and set an "in-line" rating for the company in a research note on Friday, May 2nd. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $46.61.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.